- Home
- ACHV vs XFOR Comparison
ACHV vs XFOR Comparison
Compare ACHV & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- XFOR
- Stock Information
- Founded
- ACHV N/A
- XFOR 2014
- Country
- ACHV Canada
- XFOR United States
- Employees
- ACHV N/A
- XFOR N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACHV Health Care
- XFOR Health Care
- Exchange
- ACHV Nasdaq
- XFOR Nasdaq
- Market Cap
- ACHV 126.9M
- XFOR 118.4M
- IPO Year
- ACHV N/A
- XFOR N/A
- Fundamental
- Price
- ACHV $3.17
- XFOR $0.47
- Analyst Decision
- ACHV Strong Buy
- XFOR Strong Buy
- Analyst Count
- ACHV 5
- XFOR 3
- Target Price
- ACHV $14.80
- XFOR $3.50
- AVG Volume (30 Days)
- ACHV 229.0K
- XFOR 6.8M
- Earning Date
- ACHV 03-27-2025
- XFOR 03-20-2025
- Dividend Yield
- ACHV N/A
- XFOR N/A
- EPS Growth
- ACHV N/A
- XFOR N/A
- EPS
- ACHV N/A
- XFOR N/A
- Revenue
- ACHV N/A
- XFOR $1,123,000.00
- Revenue This Year
- ACHV N/A
- XFOR N/A
- Revenue Next Year
- ACHV N/A
- XFOR $590.67
- P/E Ratio
- ACHV N/A
- XFOR N/A
- Revenue Growth
- ACHV N/A
- XFOR N/A
- 52 Week Low
- ACHV $2.84
- XFOR $0.26
- 52 Week High
- ACHV $5.59
- XFOR $1.60
- Technical
- Relative Strength Index (RSI)
- ACHV 44.06
- XFOR 41.75
- Support Level
- ACHV $3.18
- XFOR $0.46
- Resistance Level
- ACHV $3.59
- XFOR $0.54
- Average True Range (ATR)
- ACHV 0.21
- XFOR 0.05
- MACD
- ACHV 0.01
- XFOR -0.01
- Stochastic Oscillator
- ACHV 19.48
- XFOR 5.63
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.